

Cardio Update

Herzzentrum

Update vom ESC

Donnerstag, 05. September 2019



Referent: Prof. Christian Müller

Summary

- Dapagliflozin reduced the risk of worsening heart failure events and cardiovascular death, and improved symptoms in patients with HFrEF, when added to standard therapy.
- The relative and absolute risk reductions in death and hospitalization were substantial, clinically important, and consistent across important subgroups, including patients *without* T2D
- Dapagliflozin was well tolerated and the rate of treatment discontinuation was low
- Dapagliflozin offers a new approach to the treatment of HFrEF